• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Healthcare·2934.T
Share

J Frontier Co.,Ltd. Stocks

¥ 1803Last Updated 27.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

¥ 55.83M

¥ 1803
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

J Frontier Co.,Ltd. engages in the healthcare sales, medical care sales, and healthcare marketing businesses in Japan. The company operates SOKUYAKU, a platform for online medical treatment, online medication guidance, home delivery of prescription drugs, and digital transformation support for medical institutions. The company also sells health foods, health, beauty, education, healing, medicine, and medical care products through mail order; and provides product sales promotion support services. In addition, it offers Internet advertising for medical institutions and healthcare-related companies; and web marketing, in-store and TV shopping distribution, BPO support for logistics, etc. J Frontier Co.,Ltd. was incorporated in 2008 and is based in Shibuya, Japan.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.07.2026 18:30

A 10-fold growth, Korea’s golden age, and a lesson from China: Highlights from an interview with the head of Nvidia

27.07.2026 18:02

A Magnet for Startups: Why Are Fintech Startups and Neobanks Flocking to Colombia?

27.07.2026 17:40

Leather bags are no longer driving the luxury market. But a new driver has emerged.

27.07.2026 17:16

Shares of European and U.S. oil giants have plummeted along with oil prices. Is it time to sell them?

27.07.2026 16:55

Shares of the largest supplier of electric vehicle batteries soared after the company announced a buyback

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026